ABBV — AbbVie Inc.

NYSE · Health Care · Pharmaceuticals · CIK 1551152 ·
Last close
$248.76
Market Cap
$439.59B
52W High
$267.47
52W Low
$202.86
ADV30
5,929,817
Next earnings
2026-10-29
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Jun 2026 16,990,000,000 12,699,000,000 6,723,000,000 3,613,000,000 135,115,000,000 6,569,000,000 141,003,000,000
Mar 2026
Dec 2025 16,618,000,000 12,066,000,000 5,809,000,000 1,816,000,000 133,960,000,000 5,229,000,000 137,188,000,000
Sep 2025 15,776,000,000 10,472,000,000 4,584,000,000 186,000,000 133,898,000,000 5,629,000,000 136,497,000,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$19,507,000,000
Investing CF
$-6,498,000,000
Financing CF
$-12,891,000,000
CapEx
$-1,297,000,000
Dividends Paid
$-11,978,000,000
Buybacks
$-1,505,000,000
EPS Diluted TTM
$3.54
As of
2026-08-09

Balance + Analyst (yfinance extras)

Retained Earnings
$-17,333,000,000
Inventory
$5,127,000,000
Receivables
$13,824,000,000
ST Investments
$28,000,000
EBIT TTM
$11,615,000,000
Pretax Income TTM
$8,699,000,000
Interest Exp TTM
$2,916,000,000
Analysts
28

Yahoo Snapshot (yfinance, live)

Total Revenue
$64,385,998,848
EBITDA
$30,762,999,808
Free Cash Flow
$16,870,250,496
Enterprise Value
$503,951,097,856
Total Cash
$6,568,999,936
Total Debt
$70,884,999,168
Shares Out
1,767,117,285
Trailing EPS
$3.53
Book Value
$-3.36
ROE
ROA
10.5%
Div Yield
2.77%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 61,160,000,000 20,091,000,000 4,226,000,000 133,960,000,000 137,188,000,000 19,030,000,000
Dec 2024 56,334,000,000 11,894,000,000 4,278,000,000 135,161,000,000 131,797,000,000 18,806,000,000
Dec 2023 54,318,000,000 13,535,000,000 4,863,000,000 134,711,000,000 124,314,000,000 22,839,000,000
Dec 2022 58,054,000,000 18,814,000,000 11,836,000,000 138,805,000,000 121,518,000,000 24,943,000,000

TTM Snapshot

Revenues TTM
$57,541,000,000
NetIncome TTM
$10,467,000,000
OpCashFlow TTM
$0
Assets (Latest)
$135,161,000,000
Forward EPS
$16.28

Max Pain — expiry 2026-08-21

max pain strike: $240.00 · spot: $250.06 · call oi: 36,460 · put oi: 24,245
Expected Move to 2026-08-21: ±$6.87 (2.75%) — implied range $243.19$256.92 · ATM straddle on $250.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
MRK Merck & Co., Inc. $327.94B $132.92
JNJ JOHNSON & JOHNSON $628.65B $260.86
NVSEF NOVARTIS AG $300.12B $157.90
NVS NOVARTIS AG $289.52B $152.32
AZN ASTRAZENECA PLC $245.82B $158.50

News headlines (Yahoo Finance, 1h cache)

Here Are Thursday’s Top Wall Street Analyst Research Calls: Abbott Labs, AbbVie, Akamai Technologies, Five Below, Keurig Dr. Pepper, Salesforce, Stryker, StubHub, and More
2026-08-13 11:53 · Yahoo
Johnson & Johnson vs AbbVie: Safe Dividend vs Higher Yield
2026-08-12 18:30 · Yahoo
AbbVie (ABBV) Wins Canada Reimbursement Backing For Adult Migraine Treatment
2026-08-11 22:15 · Yahoo
AbbVie vs. CVS Health: Which Healthcare Stock Is a Better Buy in 2026?
2026-08-11 20:47 · Yahoo
Pfizer vs AbbVie: What's the Better Dividend Stock for Investors in 2026?
2026-08-11 17:15 · Yahoo
The Energy and Pharma Giants Quietly Funding HDV’s 3% Yield, and How Safe Each One Is
2026-08-12 16:12 · Yahoo
The Sharpest Exchanges From ABBV's Earnings Call
2026-08-13 16:10 · Yahoo
Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation
2026-08-13 13:52 · Yahoo
How ABBV Stock Moved Away From Its Peer Group
2026-08-12 20:49 · Yahoo
Amgen Stock And The Price Of A Promise
2026-08-12 19:17 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.